



## Clinical trial results:

### A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

#### Summary

EudraCT number	2010-024518-74
Trial protocol	GB SE DE NO NL AT IT ES
Global end of trial date	15 October 2013

#### Results information

Result version number	v1 (current)
This version publication date	13 July 2016
First version publication date	09 August 2015

#### Trial information

##### Trial identification

Sponsor protocol code	IPI-926-04
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	IND number: 78,428

Notes:

#### Sponsors

Sponsor organisation name	Infinity Pharmaceuticals, Inc.
Sponsor organisation address	780 Memorial Drive , Cambridge, MA, United States, 02139
Public contact	IPI-926-04 Trial Information, Infinity Pharmaceuticals, Inc., +1 617 453 1000,
Scientific contact	David A. Roth, MD, Infinity Pharmaceuticals, Inc., +1 617 453 1412,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	12 November 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 October 2012
Global end of trial reached?	Yes
Global end of trial date	15 October 2013
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

- Compare progression-free survival (PFS) in patients with metastatic or locally advanced (unresectable) chondrosarcoma administered IPI-926 or placebo.
- Evaluate the safety of IPI-926 in patients with metastatic or locally advanced(unresectable) chondrosarcoma

Protection of trial subjects:

Independent Data Monitoring Committee initiated for IPI-145-04. A group of individuals with pertinent expertise that regularly reviews accumulating data from an ongoing clinical study. The iDMC advises the Sponsor regarding the continuing safety of trial subjects, as well as the continuing validity and scientific merit of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 June 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Norway: 2
Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	Sweden: 6
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 20
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Russian Federation: 3
Country: Number of subjects enrolled	United States: 38
Country: Number of subjects enrolled	Australia: 2
Worldwide total number of subjects	105
EEA total number of subjects	59

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	82
From 65 to 84 years	23
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	152 <sup>[1]</sup>
----------------------------	--------------------

Number of subjects completed	105
------------------------------	-----

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screening failure: 47
----------------------------	-----------------------

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The number of screened patients (152) per country and per age group has been collected but has not been prespecified in the Statistical Analysis Plan. Therefore, the number of randomized patients (105) per country and per age group is indicated in the Trial information section.

### Period 1

Period 1 title	Double-blind (overall period)
----------------	-------------------------------

Is this the baseline period?	Yes
------------------------------	-----

Allocation method	Randomised - controlled
-------------------	-------------------------

Blinding used	Double blind
---------------	--------------

Roles blinded	Subject, Investigator, Monitor, Data analyst
---------------	--

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	IPI-926
------------------	---------

Arm description: -

Arm type	Experimental
----------	--------------

Investigational medicinal product name	IPI-926
--	---------

Investigational medicinal product code	PR1
--	-----

Other name	2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3Hspiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulene]-3'-yl)methanesulfonamide
------------	--

Pharmaceutical forms	Capsule
----------------------	---------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

IPI-926 will be administered at a dose of 160 mg/day, as one dose per day.

<b>Arm title</b>	Placebo
------------------	---------

Arm description: -

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
--	---------

Investigational medicinal product code	PL1
--	-----

Other name	
------------	--

Pharmaceutical forms	Capsule
----------------------	---------

Routes of administration	Oral use
--------------------------	----------

Dosage and administration details:

Doses of placebo are to be taken as one dose per day.

<b>Number of subjects in period 1</b>	IPI-926	Placebo
Started	71	34
Completed	0	0
Not completed	71	34
RECIST confirmed Disease Progression	37	19
Study termination by Sponsor	13	-
Terminated by Sponsor	-	8
Physician decision	1	-
Consent withdrawn by subject	1	1
'Clinical disease progression '	8	-
Other	7	1
Adverse event	4	2
Clinical or symptomatic disease progression	-	2
'Non-compliance with study drug '	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Double-blind
-----------------------	--------------

Reporting group description:

For each cycle during the double-blind portion of the study, 160 mg oral IPI-926 or placebo was administered daily for 28 days.

For the 71 subjects treated with IPI-926 in the double-blind phase, the median (range) duration of exposure was 10.1 (2 to 52.6) weeks. The median (range) total dose of IPI-926 received was 11360 (2240 to 49100) mg.

Reporting group values	Double-blind	Total	
Number of subjects	105	105	
Age categorical			
Units: Subjects			
Adults (18-64 years)	82	82	
From 65-84 years	23	23	
Age continuous			
Units: years			
arithmetic mean	52.8		
full range (min-max)	24 to 82	-	
Gender categorical			
Units: Subjects			
Female	31	31	
Male	74	74	

### Subject analysis sets

Subject analysis set title	IPI-926
Subject analysis set type	Full analysis

Subject analysis set description:

The full analysis set (FAS) includes all randomized patients in the treatment group assigned by randomization. The FAS is used for all efficacy analyses. The principle of an intent-to-treat analysis will be used to define the FAS population.

Subject analysis set title	Placebo
Subject analysis set type	Full analysis

Subject analysis set description:

The full analysis set (FAS) includes all randomized patients in the treatment group assigned by randomization. The FAS is used for all efficacy analyses. The principle of an intent-to-treat analysis will be used to define the FAS population.

Reporting group values	IPI-926	Placebo	
Number of subjects	71	34	
Age categorical			
Units: Subjects			
Adults (18-64 years)	53	29	
From 65-84 years	18	5	
Age continuous			
Units: years			
arithmetic mean	53.7	50.9	
full range (min-max)	24 to 82	25 to 70	

Gender categorical			
Units: Subjects			
Female	20	11	
Male	51	23	

## End points

### End points reporting groups

Reporting group title	IPI-926
Reporting group description: -	
Reporting group title	Placebo
Reporting group description: -	
Subject analysis set title	IPI-926
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set (FAS) includes all randomized patients in the treatment group assigned by randomization. The FAS is used for all efficacy analyses. The principle of an intent-to-treat analysis will be used to define the FAS population.	
Subject analysis set title	Placebo
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set (FAS) includes all randomized patients in the treatment group assigned by randomization. The FAS is used for all efficacy analyses. The principle of an intent-to-treat analysis will be used to define the FAS population.	

### Primary: PFS

End point title	PFS
End point description:	
End point type	Primary
End point timeframe: CT scan or MRI on Day 27 ( $\pm$ 2 days) of Cycles 1, 2, 4, 6, and 8, and every third cycle thereafter on Day 27 ( $\pm$ 2 days), as well as at the end of treatment.	

End point values	IPI-926	Placebo	IPI-926	Placebo
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	71	34	71	34
Units: months				
number (confidence interval 95%)	3.7 (1.87 to 3.71)	2.9 (1.84 to 4.04)	3.7 (1.87 to 3.71)	2.9 (1.84 to 4.04)

### Statistical analyses

Statistical analysis title	Kaplan Meyer estimate
Comparison groups	IPI-926 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.792
Method	Logrank



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All AEs were recorded from the time of informed consent until 30 days after the last dose of study treatment.

Adverse event reporting additional description:

Patients were instructed to report all AEs and were asked a general health status question at each study visit. All adverse events, whether volunteered or elicited, were recorded on the eCRF. An adverse event was followed until it was either resolved, had returned to baseline, or was determined to be a stable or chronic condition.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	14.1

### Reporting groups

Reporting group title	IPI-926
-----------------------	---------

Reporting group description: -

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	IPI-926	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 71 (30.99%)	8 / 34 (23.53%)	
number of deaths (all causes)	5	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to neck			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour pain			
subjects affected / exposed	1 / 71 (1.41%)	2 / 34 (5.88%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural			

complications			
Periprosthetic fracture			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Lymphoedema			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Spinal cord compression			
subjects affected / exposed	2 / 71 (2.82%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraparesis			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Disease progression			
subjects affected / exposed	3 / 71 (4.23%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 0	
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Enterocutaneous fistula			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Constipation</b>			
subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pulmonary embolism			
subjects affected / exposed	2 / 71 (2.82%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory failure</b>			
subjects affected / exposed	2 / 71 (2.82%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Acute respiratory distress syndrome</b>			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dyspnoea</b>			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Haemoptysis</b>			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pneumothorax			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary hesitation			
subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 71 (1.41%)	0 / 34 (0.00%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	0 / 71 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 22	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 71 (2.82%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Arthritis bacterial subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Septic shock subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Urinary tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Urosepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 71 (1.41%) 0 / 22 0 / 0	0 / 34 (0.00%) 0 / 8 0 / 0	
Clostridium difficile colitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 71 (0.00%) 0 / 22 0 / 0	1 / 34 (2.94%) 0 / 8 0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	IPI-926	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	67 / 71 (94.37%)	29 / 34 (85.29%)	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	28 / 71 (39.44%)	0 / 34 (0.00%)	
occurrences (all)	67	29	
Aspartate aminotransferase increased			
subjects affected / exposed	22 / 71 (30.99%)	0 / 34 (0.00%)	
occurrences (all)	67	29	
Blood alkaline phosphatase increased			
subjects affected / exposed	12 / 71 (16.90%)	1 / 34 (2.94%)	
occurrences (all)	67	29	
Blood bilirubin increased			
subjects affected / exposed	5 / 71 (7.04%)	0 / 34 (0.00%)	
occurrences (all)	67	29	
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	8 / 71 (11.27%)	0 / 34 (0.00%)	
occurrences (all)	67	29	
Headache			
subjects affected / exposed	6 / 71 (8.45%)	1 / 34 (2.94%)	
occurrences (all)	67	29	
Dizziness			
subjects affected / exposed	5 / 71 (7.04%)	0 / 34 (0.00%)	
occurrences (all)	67	29	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	21 / 71 (29.58%)	2 / 34 (5.88%)	
occurrences (all)	67	29	
Constipation			
subjects affected / exposed	21 / 71 (29.58%)	2 / 34 (5.88%)	
occurrences (all)	67	29	
Vomiting			

subjects affected / exposed occurrences (all)	11 / 71 (15.49%) 67	2 / 34 (5.88%) 29	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	9 / 71 (12.68%) 67	2 / 34 (5.88%) 29	
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)	6 / 71 (8.45%) 67  4 / 71 (5.63%) 67	0 / 34 (0.00%) 29  0 / 34 (0.00%) 29	
Musculoskeletal and connective tissue disorders Muscle spasms subjects affected / exposed occurrences (all)  Back pain subjects affected / exposed occurrences (all)	12 / 71 (16.90%) 67  4 / 71 (5.63%) 67	4 / 34 (11.76%) 29  0 / 34 (0.00%) 29	
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Clostridium difficile colitis subjects affected / exposed occurrences (all)	4 / 71 (5.63%) 67  1 / 71 (1.41%) 67  0 / 71 (0.00%) 67	0 / 34 (0.00%) 29  3 / 34 (8.82%) 29  2 / 34 (5.88%) 29	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	14 / 71 (19.72%) 67	3 / 34 (8.82%) 29	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 January 2011	Protocol Amendment 1
07 April 2011	IMPD Amendment
19 April 2011	IB Edition 04
19 August 2011	IB Edition 05
07 September 2011	Protocol Amendment 2
09 September 2011	IMPD Amendment
23 December 2011	IMPD Amendment
27 March 2012	Protocol Amendment 3
27 March 2012	IB Edition 06

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
18 June 2012	On 14 June 2012, a planned futility analysis of data from the study concluded that treatment with IPI-926 was similar to placebo and, therefore, the trial would not meet its primary endpoint. Based on this interim analysis, Infinity announced on 18 June 2012 it was stopping the trial. No formal efficacy or exploratory analyses were performed.	-

Notes:

### Limitations and caveats

None reported